|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11-12
|
|
pubmed:dateCreated |
2010-11-5
|
|
pubmed:abstractText |
Infliximab is effective for induction and maintenance of remission in patients with Crohn's disease. There are few data, however, examining effect of infliximab therapy on management costs of Crohn's disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1365-2036
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2010 Blackwell Publishing Ltd.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1357-63
|
|
pubmed:meshHeading |
pubmed-meshheading:21050238-Adolescent,
pubmed-meshheading:21050238-Adult,
pubmed-meshheading:21050238-Antibodies, Monoclonal,
pubmed-meshheading:21050238-Cost-Benefit Analysis,
pubmed-meshheading:21050238-Crohn Disease,
pubmed-meshheading:21050238-Female,
pubmed-meshheading:21050238-Gastrointestinal Agents,
pubmed-meshheading:21050238-Great Britain,
pubmed-meshheading:21050238-Health Care Costs,
pubmed-meshheading:21050238-Humans,
pubmed-meshheading:21050238-Male,
pubmed-meshheading:21050238-Treatment Outcome,
pubmed-meshheading:21050238-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
|
|
pubmed:affiliation |
Leeds Gastroenterology Institute, The Leeds Teaching Hospitals NHS Trust, UK. michael.sprakes@leedsth.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
